Immune responses after live attenuated influenza vaccination
Since 2003 (US) and 2012 (Europe) the live attenuated influenza vaccine (LAIV) has been used as an alternative to the traditional inactivated influenza vaccines (IIV). The immune responses elicted by LAIV mimic natural infection and have been found to provide broader clinical protection in children...
Gespeichert in:
| Veröffentlicht in: | Human vaccines & immunotherapeutics 2018-03, Vol.14 (3), p.571-578 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 578 |
|---|---|
| container_issue | 3 |
| container_start_page | 571 |
| container_title | Human vaccines & immunotherapeutics |
| container_volume | 14 |
| creator | Mohn, Kristin G.-I. Smith, Ingrid Sjursen, Haakon Cox, Rebecca Jane |
| description | Since 2003 (US) and 2012 (Europe) the live attenuated influenza vaccine (LAIV) has been used as an alternative to the traditional inactivated influenza vaccines (IIV). The immune responses elicted by LAIV mimic natural infection and have been found to provide broader clinical protection in children compared to the IIVs. However, our knowledge of the detailed immunological mechanisims induced by LAIV remain to be fully elucidated, and despite 14 years on the global market, there exists no correlate of protection. Recently, matters are further complicated by differing efficacy data from the US and Europe which are not understood. Better understanding of the immune responses after LAIV may aid in achieving the ultimate goal of a future "universal influenza vaccine". In this review we aim to cover the current understanding of the immune responses induced after LAIV. |
| doi_str_mv | 10.1080/21645515.2017.1377376 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5861782</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_594b4c0169ba4441a9ad1b5da9465849</doaj_id><sourcerecordid>1941360313</sourcerecordid><originalsourceid>FETCH-LOGICAL-c534t-aa793677f20462c3bd52d0e67f35bd97b32029aed6fab4cf5d56f319eed1f2ef3</originalsourceid><addsrcrecordid>eNp9kU2LFDEQhhtR3GXdn6D00cuM-U4HRJTFj4EFLwreQnVSWbN0J2PSPcv66-1xZgf3Yi4JlbeeKnia5iUla0o68oZRJaSkcs0I1WvKteZaPWnO9_WVlOLH09ObyrPmstZbshxNmFDqeXPGOsO5UuK8ebsZxzlhW7Buc6pYWwgTlnaIO2xhmjDNMKFvYwrDjOk3tDtwLiaYYk4vmmcBhoqXx_ui-f7p47erL6vrr583Vx-uV05yMa0AtOFK68CIUMzx3kvmCSoduOy90T1nhBlArwL0wgXppQqcGkRPA8PAL5rNgesz3NptiSOUe5sh2r-FXG4slCm6Aa00YkEQqkwPQggKBjztpQcjlOyEWVjvDqzt3I_oHaapwPAI-vgnxZ_2Ju-s7BTVHVsAr4-Akn_NWCc7xupwGCBhnqulRlCuCKd8icpD1JVca8FwGkOJ3Yu0DyLtXqQ9ilz6Xv2746nrQdsSeH8ILFpyGeEul8HbCe6HXEKB5GK1_P8z_gCRfa3l</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1941360313</pqid></control><display><type>article</type><title>Immune responses after live attenuated influenza vaccination</title><source>MEDLINE</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Mohn, Kristin G.-I. ; Smith, Ingrid ; Sjursen, Haakon ; Cox, Rebecca Jane</creator><creatorcontrib>Mohn, Kristin G.-I. ; Smith, Ingrid ; Sjursen, Haakon ; Cox, Rebecca Jane</creatorcontrib><description>Since 2003 (US) and 2012 (Europe) the live attenuated influenza vaccine (LAIV) has been used as an alternative to the traditional inactivated influenza vaccines (IIV). The immune responses elicted by LAIV mimic natural infection and have been found to provide broader clinical protection in children compared to the IIVs. However, our knowledge of the detailed immunological mechanisims induced by LAIV remain to be fully elucidated, and despite 14 years on the global market, there exists no correlate of protection. Recently, matters are further complicated by differing efficacy data from the US and Europe which are not understood. Better understanding of the immune responses after LAIV may aid in achieving the ultimate goal of a future "universal influenza vaccine". In this review we aim to cover the current understanding of the immune responses induced after LAIV.</description><identifier>ISSN: 2164-5515</identifier><identifier>EISSN: 2164-554X</identifier><identifier>DOI: 10.1080/21645515.2017.1377376</identifier><identifier>PMID: 28933664</identifier><language>eng</language><publisher>United States: Taylor & Francis</publisher><subject>Animals ; Antibodies, Viral - immunology ; Antibody ; Humans ; immune response ; Influenza Vaccines - immunology ; Influenza, Human - immunology ; Influenza, Human - prevention & control ; live attenuated influenza vaccine (LAIV) ; Orthomyxoviridae Infections - immunology ; Reviews ; T-cell ; Vaccination - methods ; Vaccines, Attenuated - immunology ; Vaccines, Inactivated - immunology</subject><ispartof>Human vaccines & immunotherapeutics, 2018-03, Vol.14 (3), p.571-578</ispartof><rights>2018 The Author(s). Published with license by Taylor & Francis © Kristin G.-I. Mohn, Ingrid Smith, Haakon Sjursen, and Rebecca Jane Cox 2018</rights><rights>2018 The Author(s). Published with license by Taylor & Francis 2018 The Author(s)</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c534t-aa793677f20462c3bd52d0e67f35bd97b32029aed6fab4cf5d56f319eed1f2ef3</citedby><cites>FETCH-LOGICAL-c534t-aa793677f20462c3bd52d0e67f35bd97b32029aed6fab4cf5d56f319eed1f2ef3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5861782/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5861782/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28933664$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mohn, Kristin G.-I.</creatorcontrib><creatorcontrib>Smith, Ingrid</creatorcontrib><creatorcontrib>Sjursen, Haakon</creatorcontrib><creatorcontrib>Cox, Rebecca Jane</creatorcontrib><title>Immune responses after live attenuated influenza vaccination</title><title>Human vaccines & immunotherapeutics</title><addtitle>Hum Vaccin Immunother</addtitle><description>Since 2003 (US) and 2012 (Europe) the live attenuated influenza vaccine (LAIV) has been used as an alternative to the traditional inactivated influenza vaccines (IIV). The immune responses elicted by LAIV mimic natural infection and have been found to provide broader clinical protection in children compared to the IIVs. However, our knowledge of the detailed immunological mechanisims induced by LAIV remain to be fully elucidated, and despite 14 years on the global market, there exists no correlate of protection. Recently, matters are further complicated by differing efficacy data from the US and Europe which are not understood. Better understanding of the immune responses after LAIV may aid in achieving the ultimate goal of a future "universal influenza vaccine". In this review we aim to cover the current understanding of the immune responses induced after LAIV.</description><subject>Animals</subject><subject>Antibodies, Viral - immunology</subject><subject>Antibody</subject><subject>Humans</subject><subject>immune response</subject><subject>Influenza Vaccines - immunology</subject><subject>Influenza, Human - immunology</subject><subject>Influenza, Human - prevention & control</subject><subject>live attenuated influenza vaccine (LAIV)</subject><subject>Orthomyxoviridae Infections - immunology</subject><subject>Reviews</subject><subject>T-cell</subject><subject>Vaccination - methods</subject><subject>Vaccines, Attenuated - immunology</subject><subject>Vaccines, Inactivated - immunology</subject><issn>2164-5515</issn><issn>2164-554X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>0YH</sourceid><sourceid>EIF</sourceid><sourceid>DOA</sourceid><recordid>eNp9kU2LFDEQhhtR3GXdn6D00cuM-U4HRJTFj4EFLwreQnVSWbN0J2PSPcv66-1xZgf3Yi4JlbeeKnia5iUla0o68oZRJaSkcs0I1WvKteZaPWnO9_WVlOLH09ObyrPmstZbshxNmFDqeXPGOsO5UuK8ebsZxzlhW7Buc6pYWwgTlnaIO2xhmjDNMKFvYwrDjOk3tDtwLiaYYk4vmmcBhoqXx_ui-f7p47erL6vrr583Vx-uV05yMa0AtOFK68CIUMzx3kvmCSoduOy90T1nhBlArwL0wgXppQqcGkRPA8PAL5rNgesz3NptiSOUe5sh2r-FXG4slCm6Aa00YkEQqkwPQggKBjztpQcjlOyEWVjvDqzt3I_oHaapwPAI-vgnxZ_2Ju-s7BTVHVsAr4-Akn_NWCc7xupwGCBhnqulRlCuCKd8icpD1JVca8FwGkOJ3Yu0DyLtXqQ9ilz6Xv2746nrQdsSeH8ILFpyGeEul8HbCe6HXEKB5GK1_P8z_gCRfa3l</recordid><startdate>20180304</startdate><enddate>20180304</enddate><creator>Mohn, Kristin G.-I.</creator><creator>Smith, Ingrid</creator><creator>Sjursen, Haakon</creator><creator>Cox, Rebecca Jane</creator><general>Taylor & Francis</general><general>Taylor & Francis Group</general><scope>0YH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20180304</creationdate><title>Immune responses after live attenuated influenza vaccination</title><author>Mohn, Kristin G.-I. ; Smith, Ingrid ; Sjursen, Haakon ; Cox, Rebecca Jane</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c534t-aa793677f20462c3bd52d0e67f35bd97b32029aed6fab4cf5d56f319eed1f2ef3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Animals</topic><topic>Antibodies, Viral - immunology</topic><topic>Antibody</topic><topic>Humans</topic><topic>immune response</topic><topic>Influenza Vaccines - immunology</topic><topic>Influenza, Human - immunology</topic><topic>Influenza, Human - prevention & control</topic><topic>live attenuated influenza vaccine (LAIV)</topic><topic>Orthomyxoviridae Infections - immunology</topic><topic>Reviews</topic><topic>T-cell</topic><topic>Vaccination - methods</topic><topic>Vaccines, Attenuated - immunology</topic><topic>Vaccines, Inactivated - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mohn, Kristin G.-I.</creatorcontrib><creatorcontrib>Smith, Ingrid</creatorcontrib><creatorcontrib>Sjursen, Haakon</creatorcontrib><creatorcontrib>Cox, Rebecca Jane</creatorcontrib><collection>Taylor & Francis Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Human vaccines & immunotherapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mohn, Kristin G.-I.</au><au>Smith, Ingrid</au><au>Sjursen, Haakon</au><au>Cox, Rebecca Jane</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immune responses after live attenuated influenza vaccination</atitle><jtitle>Human vaccines & immunotherapeutics</jtitle><addtitle>Hum Vaccin Immunother</addtitle><date>2018-03-04</date><risdate>2018</risdate><volume>14</volume><issue>3</issue><spage>571</spage><epage>578</epage><pages>571-578</pages><issn>2164-5515</issn><eissn>2164-554X</eissn><abstract>Since 2003 (US) and 2012 (Europe) the live attenuated influenza vaccine (LAIV) has been used as an alternative to the traditional inactivated influenza vaccines (IIV). The immune responses elicted by LAIV mimic natural infection and have been found to provide broader clinical protection in children compared to the IIVs. However, our knowledge of the detailed immunological mechanisims induced by LAIV remain to be fully elucidated, and despite 14 years on the global market, there exists no correlate of protection. Recently, matters are further complicated by differing efficacy data from the US and Europe which are not understood. Better understanding of the immune responses after LAIV may aid in achieving the ultimate goal of a future "universal influenza vaccine". In this review we aim to cover the current understanding of the immune responses induced after LAIV.</abstract><cop>United States</cop><pub>Taylor & Francis</pub><pmid>28933664</pmid><doi>10.1080/21645515.2017.1377376</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2164-5515 |
| ispartof | Human vaccines & immunotherapeutics, 2018-03, Vol.14 (3), p.571-578 |
| issn | 2164-5515 2164-554X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5861782 |
| source | MEDLINE; PubMed Central; Alma/SFX Local Collection |
| subjects | Animals Antibodies, Viral - immunology Antibody Humans immune response Influenza Vaccines - immunology Influenza, Human - immunology Influenza, Human - prevention & control live attenuated influenza vaccine (LAIV) Orthomyxoviridae Infections - immunology Reviews T-cell Vaccination - methods Vaccines, Attenuated - immunology Vaccines, Inactivated - immunology |
| title | Immune responses after live attenuated influenza vaccination |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T09%3A30%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immune%20responses%20after%20live%20attenuated%20influenza%20vaccination&rft.jtitle=Human%20vaccines%20&%20immunotherapeutics&rft.au=Mohn,%20Kristin%20G.-I.&rft.date=2018-03-04&rft.volume=14&rft.issue=3&rft.spage=571&rft.epage=578&rft.pages=571-578&rft.issn=2164-5515&rft.eissn=2164-554X&rft_id=info:doi/10.1080/21645515.2017.1377376&rft_dat=%3Cproquest_pubme%3E1941360313%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1941360313&rft_id=info:pmid/28933664&rft_doaj_id=oai_doaj_org_article_594b4c0169ba4441a9ad1b5da9465849&rfr_iscdi=true |